Detalhe da pesquisa
1.
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lancet
; 401(10382): 1091-1102, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36924778
2.
Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
BJOG
; 2024 Feb 06.
Artigo
Inglês
| MEDLINE | ID: mdl-38320967
3.
Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
J Infect Chemother
; 26(1): 43-50, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31624029
4.
Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
J Infect Chemother
; 26(6): 611-618, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32165072
5.
Neuropathic pain: A patient-centred approach to measuring outcomes.
Health Expect
; 21(4): 774-786, 2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29656511
6.
Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
Maturitas
; : 107999, 2024 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-38749864
7.
Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Menopause
; 31(6): 512-521, 2024 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38626380
8.
Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
Menopause
; 31(4): 247-257, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38517210
9.
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Obstet Gynecol
; 141(4): 737-747, 2023 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36897180
10.
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
J Clin Endocrinol Metab
; 108(8): 1981-1997, 2023 Jul 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36734148
11.
Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies.
Antimicrob Agents Chemother
; 56(4): 2037-47, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22290969
12.
Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS Sleep Disturbance and Sleep-Related Impairment measures for assessment of VMS impact on sleep.
J Patient Rep Outcomes
; 5(1): 37, 2021 Apr 26.
Artigo
Inglês
| MEDLINE | ID: mdl-33900486
13.
The Symptoms and Impact of Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Conceptual Model of the Patient Experience.
Adv Ther
; 36(12): 3390-3408, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31612357
14.
Correction to: Qualitative study: burden of menopause-associated vasomotor symptoms (VMS) and validation of PROMIS sleep disturbance and sleep-related impairment measures for assessment of VMS impact on sleep.
J Patient Rep Outcomes
; 5(1): 42, 2021 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34061278
15.
A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment.
J Manag Care Spec Pharm
; 21(10): 854-60, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26402386